Danaher Reports Fourth Quarter and Full Year 2025 Results

Core Insights - Danaher Corporation reported strong financial results for Q4 and full year 2025, with net earnings of $1.2 billion for Q4 and $3.6 billion for the full year, reflecting a diluted earnings per share of $1.66 and $5.03 respectively [1][2] - The company experienced a revenue increase of 4.5% year-over-year in Q4, totaling $6.8 billion, and a 3.0% increase for the full year, reaching $24.6 billion [1][2] - Non-GAAP adjusted diluted net earnings per share grew by 4.0% in Q4 to $2.23 and by 4.5% for the full year to $7.80 [1][2] Financial Performance - Q4 2025 net earnings: $1.2 billion, diluted EPS: $1.66; Full year 2025 net earnings: $3.6 billion, diluted EPS: $5.03 [1][2] - Q4 2025 revenues: $6.8 billion, a 4.5% increase; Full year 2025 revenues: $24.6 billion, a 3.0% increase [1][2] - Operating cash flow for Q4 was $2.1 billion, and for the full year, it was $6.4 billion; Non-GAAP free cash flow was $1.8 billion for Q4 and $5.3 billion for the full year [1][2] Innovation Highlights - Danaher launched several innovative products in 2025, enhancing its position in life sciences and diagnostics [1] - Notable product launches included Cytiva's expanded Xcellerex X-platform bioreactor, SCIEX's ZenoTOF 8600 mass spectrometer, and Cepheid's FDA-cleared Xpert GI Panel [1] Market Outlook - The company anticipates continued gradual improvement in end markets through 2026, supported by its differentiated portfolio and strong balance sheet [1] - For Q1 2026, Danaher expects non-GAAP core revenue growth in the low-single digit percentage range, and for the full year, a growth of 3% to 6% [1][2] Segment Performance - Total sales growth for Q4 2025 was 4.5%, with biotechnology segment growth at 9.0%, life sciences at 2.5%, and diagnostics at 3.0% [4] - For the full year 2025, total sales growth was 3.0%, with biotechnology at 8.0%, life sciences flat, and diagnostics at 1.5% [4] Cash Flow and Financial Ratios - Q4 2025 operating cash flow conversion ratio was 1.79, and for the full year, it was 1.78 [5] - Free cash flow for Q4 was $1.8 billion, with a conversion ratio of 1.50, and for the full year, it was $5.3 billion with a conversion ratio of 1.47 [5]